Clinical Trial Update: SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk [Phase 3]

View source ↗

Summary

Phase 3 trial update on an SGLT-2 inhibitor assessing effects on myocardial perfusion, function, and metabolism in type 2 diabetes patients at high cardiovascul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Type 2 Diabetes Mellitus

Snippet

Sponsor: Caroline M Kistorp | Conditions: Type2 Diabetes Mellitus | Phase 3 | Status: COMPLETED